Biopharmaceutical company Immunomedics reported revenues of $1.1 million and a net loss of $4.2 million for the first quarter of fiscal year 2005 (end-September 30).
The Morris Plains, NJ-based company reported revenues of $1.2 million and a net loss of $5.2 million for the same period last year. The decline in net loss was primarily due to the settlement of a patent lawsuit.
Immunomedics recently reported updated clinical results from a phase II study of epratuzumab in systemic lupus erythematosus (SLE). The company is also planning future registration trials with epratuzumab in patients with non-Hodgkin's lymphoma (NHL). The FDA and the European regulatory authorities have already accepted the NHL trial design.
By AuntMinnie.com staff writers
November 4, 2004
Related Reading
Settlement in Immunomedics patent case, September 30, 2004
Immunomedics revenues sag, September 9, 2004
Immunomedics to raise $15 million, August 2, 2004
Settlement for Immunomedics, CIS bio, July 8, 2004
Immunomedics scores favorable patent ruling, June 25, 2004
Copyright © 2004 AuntMinnie.com
